These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25076712)

  • 1. Polycythemia vera syndrome--as a protrombothic state.
    Bădulescu OV; Ciocoiu M; Bararu I; Mocanu M; Bădescu M
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):432-8. PubMed ID: 25076712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
    Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
    Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of hemostatic balance in blood from patients with polycythemia vera by means of thromboelastography: the effect of isovolemic erythrocytapheresis.
    Rusak T; Ciborowski M; Uchimiak-Owieczko A; Piszcz J; Radziwon P; Tomasiak M
    Platelets; 2012; 23(6):455-62. PubMed ID: 22098131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients.
    Bachleitner-Hofmann T; Grumbeck E; Gisslinger H
    Thromb Res; 2003; 112(4):229-32. PubMed ID: 14987916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort.
    Sakkinen PA; Cushman M; Psaty BM; Kuller LH; Bajaj SP; Sabharwal AK; Boineau R; Macy E; Tracy RP
    Thromb Haemost; 1998 Jul; 80(1):134-9. PubMed ID: 9684799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory investigations and prediction of thrombotic risk in polycythemia vera.
    Boneu B
    Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):183-5. PubMed ID: 8036139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum vascular endothelial growth factor levels in patients with polycythemia vera and thrombotic complications.
    Cacciola RR; Di Francesco E; Giustolisi R; Cacciola E
    Haematologica; 2002 Jul; 87(7):774-5. PubMed ID: 12091131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of anticoagulant proteins detection in patients with thrombotic events].
    Zheng CC; Wu JS; Ding KY; Li J; Hu HJ; Ding XL; Liu X; Cai XY; Zhu WB
    Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):264-7. PubMed ID: 19731829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.
    Cancelas JA; García-Avello A; García-Frade LJ
    Thromb Res; 1994 Sep; 75(5):513-20. PubMed ID: 7992252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.
    Barbui T; Vannucchi AM; Carobbio A; Thiele J; Rumi E; Gisslinger H; Rodeghiero F; Randi ML; Rambaldi A; Pieri L; Pardanani A; Passamonti F; Finazzi G; Tefferi A
    Am J Hematol; 2015 May; 90(5):434-7. PubMed ID: 25683038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein C, S and antithrombin III levels in patients with acute mechanical valve thrombosis.
    Tütün U; Ulus AT; Aksöyek A; Kaplan S; Ayaz S; Yilmaz S; Birincioglu L; Katircioglu SF
    Panminerva Med; 2002 Dec; 44(4):359-63. PubMed ID: 12434119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.
    Falanga A; Marchetti M; Barbui T; Smith CW
    Semin Hematol; 2005 Oct; 42(4):239-47. PubMed ID: 16210037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera.
    Benevolo G; Marchetti M; Melchio R; Beggiato E; Sartori C; Biolé CA; Rapezzi D; Bruno B; Milan A
    Vasc Health Risk Manag; 2023; 19():765-778. PubMed ID: 38025519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular events and intensity of treatment in polycythemia vera.
    Marchioli R; Finazzi G; Specchia G; Cacciola R; Cavazzina R; Cilloni D; De Stefano V; Elli E; Iurlo A; Latagliata R; Lunghi F; Lunghi M; Marfisi RM; Musto P; Masciulli A; Musolino C; Cascavilla N; Quarta G; Randi ML; Rapezzi D; Ruggeri M; Rumi E; Scortechini AR; Santini S; Scarano M; Siragusa S; Spadea A; Tieghi A; Angelucci E; Visani G; Vannucchi AM; Barbui T;
    N Engl J Med; 2013 Jan; 368(1):22-33. PubMed ID: 23216616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.
    Yesilova AM; Yavuzer S; Yavuzer H; Cengiz M; Toprak ID; Hanedar E; Ar MC; Baslar Z
    Int J Hematol; 2017 Jan; 105(1):70-78. PubMed ID: 27699575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.